Expressnews
Chennai, India | 4 February 2025: MrMed, a direct-to-patientplatform for critical care and super-specialty medicines, today announced a new phase of accelerated growth, driven by expanded physical infrastructure, enhanced cold-chain capabilities, and a widening national footprint.
Recognising the importance of timely access to life-saving and temperature-sensitive medicines, MrMed has expanded its physical presence with the establishment of on-ground operations in Guwahati, alongside its existing presence in Chennai, Delhi and Bengaluru. This expansion is aimed at strengthening last-mile access and improving fulfilment timelines across regions.
As part of its infrastructure expansion, the company has also launched an offline cold-chain storage facility in Bengaluru, reinforcing the city’s role as a strategic hub for faster fulfilmentand improved patient access across Karnataka and the wider South India region. Chennai continues to serve as MrMed’scentral operations and pharmacy hub.
MrMed is further advancing plans to expand its physical infrastructure across additional cities in India, with a continued focus on strengthening last-mile delivery for critical and temperature-sensitive medicines.
“Access to critical care medicines should not be determined by a patient’s location,” said Devashish Singh, Co-founder & CEO, MrMed. “Our focus has been on building reliable, compliant systems that make super-specialty therapies accessible at scale, ensuring patients can continue their treatment without disruption—even beyond large metro hospitals.”
Looking ahead, MrMed is expanding its role within the healthcare ecosystem by entering allied super-specialty healthcare services, including home-based cancer care offerings such as nurse-led infusions and pre- and post-chemotherapy support. These initiatives aim to reduce hospital visits and improve continuity of care for patients undergoing extended treatment cycles.
“While access to speciality medicines remains core to what we do, we’re increasingly seeing the need to support patients beyond just drug delivery,” said Saurab Jain, Co-founder, MrMed. “Long treatment cycles, especially in oncology, require continuity of care at home. Expanding into allied super-specialty services allows us to support patients through nurse-led infusions and pre- and post-chemotherapy care, while reducing the need for frequent hospital visits.”
Unlike platforms that focus primarily on oncology, MrMedoperates across a broader spectrum of super-specialty and critical care therapies, including medicines used to treat cancer, HIV, hepatitis, rare diseases, and other complex conditions. Many of these therapies are not routinely stocked by neighborhoodpharmacies due to cost, regulatory requirements, and cold-chain constraints.
MrMed works with authorized distributors of leading global and Indian pharmaceutical companies, including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind, ensuring compliant sourcing and reliable access to life-saving therapies for patients across the country.
